Diabetes insipidus natural history, complications and prognosis: Difference between revisions
| Line 32: | Line 32: | ||
==Prognosis== | ==Prognosis== | ||
The prognosis of diabetes insipidus is good as long as the underlying cause is identified early before the onset of complications and treated early. | |||
==References== | ==References== | ||
Revision as of 15:39, 13 July 2017
|
Diabetes insipidus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diabetes insipidus natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Diabetes insipidus natural history, complications and prognosis |
|
FDA on Diabetes insipidus natural history, complications and prognosis |
|
CDC on Diabetes insipidus natural history, complications and prognosis |
|
Diabetes insipidus natural history, complications and prognosis in the news |
|
Blogs on Diabetes insipidus natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Natural History
Diabetes insipidus if left untreated results in polyuria, nocturia, and polydipsia. This leads to an elevation in serum sodium and osmolality. The hyperosmolarity seen in this patients may also present with neurologic symptoms such as confusion, altered mental status, seizures, coma and death.
The serum sodium concentration in untreated CDI is often in the high to normal range. This is required in order to provide the sensation of thirst in a patient and stimulate drinking in order to replace the water lost in the urine. However in patients that have some form of central nervous disorders, moderate to severe hypernatremia can develop as thirst is impaired or cannot be expressed. This can also occur in infants and young children who cannot independently access free water, and in the postoperative period in patients with unrecognized diabetes insipidus (DI).
Patients with CDI may develop decreased bone mineral density at the lumbar spine and femoral neck, even in those treated with desmopressin (dDAVP).[1] It is unclear how the deficiency of ADH results in bone loss, particularly since treatment fails to prevent bone disease. However, since ADH acts upon both V1 and V2 receptors and desmopressin principally upon V2 receptors, one possible mechanism is that activation of V1 receptors stimulates bone formation.
Complications
There are two major complications of untreated diabetes insipidus. They are;
Dehydration: Due to the inability of the body to retain water, patients with diabetes insipidus are prone to dehydration if the water lost is not appropriately restored by giving IV fluids in the hospital as oral drinking of water may not be sufficient to restore lost water at the same rate especially in infants and the elderly. It is important to watch out for signs and symptoms of dehydration which include;
- Dizziness or light-headedness
- Headache
- Dry mouth and lips
- Sunken eyes and fontanelles in infants and children
- Confusion and irritability
Electrolyte imbalance: Diabetes insipidus can also cause an electrolyte imbalance. Some of the electrolyte imbalances include hypernatremia from polyuria (seen in both central and nephrogenic DI), hyponatremia from polydipsia ( seen in psychogenic DI), Hypokalemia, hypercalcemia etc. Polydipsia can cause an increase in the concentration of these electrolytes simply because of decrease in the plasma concentration of the blood. Dehydration disrupts other functions of the body, such as the way muscles work. It is important to watch out for features such as;
- Headache
- Fatigue
- Irritability
- Myalgias
- Palpitations
Prognosis
The prognosis of diabetes insipidus is good as long as the underlying cause is identified early before the onset of complications and treated early.
References
- ↑ Pivonello R, Colao A, Di Somma C, Facciolli G, Klain M, Faggiano A, Salvatore M, Lombardi G (1998). "Impairment of bone status in patients with central diabetes insipidus". J. Clin. Endocrinol. Metab. 83 (7): 2275–80. doi:10.1210/jcem.83.7.4987. PMID 9661594.